Isola J - Search Results

1

Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation.

Barok M, Puhka M, Vereb G, Szollosi J, Isola J, Joensuu H. Barok M, et al. Among authors: isola j. BMC Cancer. 2018 May 2;18(1):504. doi: 10.1186/s12885-018-4418-2. BMC Cancer. 2018. PMID: 29720111 Free PMC article.

2

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.

Barok M, Isola J, Pályi-Krekk Z, Nagy P, Juhász I, Vereb G, Kauraniemi P, Kapanen A, Tanner M, Vereb G, Szöllösi J. Barok M, et al. Among authors: isola j. Mol Cancer Ther. 2007 Jul;6(7):2065-72. doi: 10.1158/1535-7163.MCT-06-0766. Mol Cancer Ther. 2007. PMID: 17620435

3

Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.

Pályi-Krekk Z, Barok M, Isola J, Tammi M, Szöllosi J, Nagy P. Pályi-Krekk Z, et al. Among authors: isola j. Eur J Cancer. 2007 Nov;43(16):2423-33. doi: 10.1016/j.ejca.2007.08.018. Eur J Cancer. 2007. PMID: 17911008

4

Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.

Barok M, Tanner M, Köninki K, Isola J. Barok M, et al. Among authors: isola j. Cancer Lett. 2011 Jul 28;306(2):171-9. doi: 10.1016/j.canlet.2011.03.002. Epub 2011 Apr 1. Cancer Lett. 2011. PMID: 21458915

5

Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.

Barok M, Tanner M, Köninki K, Isola J. Barok M, et al. Among authors: isola j. Breast Cancer Res. 2011 Apr 21;13(2):R46. doi: 10.1186/bcr2868. Breast Cancer Res. 2011. PMID: 21510863 Free PMC article.

6

Trastuzumab emtansine: mechanisms of action and drug resistance.

Barok M, Joensuu H, Isola J. Barok M, et al. Among authors: isola j. Breast Cancer Res. 2014 Mar 5;16(2):209. doi: 10.1186/bcr3621. Breast Cancer Res. 2014. PMID: 24887180 Free PMC article. Review.

7

A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine.

Le Joncour V, Martins A, Puhka M, Isola J, Salmikangas M, Laakkonen P, Joensuu H, Barok M. Le Joncour V, et al. Among authors: isola j. Mol Cancer Ther. 2019 Oct;18(10):1721-1730. doi: 10.1158/1535-7163.MCT-19-0207. Epub 2019 Jul 10. Mol Cancer Ther. 2019. PMID: 31292166

8

ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.

Barok M, Le Joncour V, Martins A, Isola J, Salmikangas M, Laakkonen P, Joensuu H. Barok M, et al. Among authors: isola j. Cancer Lett. 2020 Mar 31;473:156-163. doi: 10.1016/j.canlet.2019.12.037. Epub 2020 Jan 2. Cancer Lett. 2020. PMID: 31904483

9

Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines.

Mocanu MM, Fazekas Z, Petrás M, Nagy P, Sebestyén Z, Isola J, Tímár J, Park JW, Vereb G, Szöllosi J. Mocanu MM, et al. Among authors: isola j. Cancer Lett. 2005 Sep 28;227(2):201-12. doi: 10.1016/j.canlet.2005.01.028. Cancer Lett. 2005. PMID: 16112423

10

Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.

Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G. Zsebik B, et al. Among authors: isola j. Immunol Lett. 2006 Apr 15;104(1-2):146-55. doi: 10.1016/j.imlet.2005.11.018. Epub 2005 Dec 12. Immunol Lett. 2006. PMID: 16384610

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

356 results

Search Page

Filters